In part three of this special interview with DIC publisher Steve Freed, Dr. Stanley Schwartz discusses how the new beta-cell classification supports a patient-centric, "precision medicine" approach to diabetes care, and enables more targeted treatments for hyperglycemia.

In part four of this special interview with DIC publisher Steve Freed, Dr. Stanley Schwartz discusses the need for better markers in improving individualization of diabetes patient care.

In part five of this special interview with DIC publisher Steve Freed, Dr. Stanley Schwartz discusses in-depth the mechanisms by which beta cell damage contributes to hyperglycemia and the targeted treatments for mediating pathways of hyperglycemia.

In part six of this special interview with DIC publisher Steve Freed, Dr. Stanley Schwartz discusses the role of gene defects within the beta cell in monogenic diabetes. In terms of prediabetes, since beta cell damage exists before the development of diabetes, better markers may help in prevention.

In part seven of this special interview with DIC publisher Steve Freed, Dr. Stanley Schwartz discusses the supporters of the new classification of diabetes, such as the role of SGLT-2 inhibitors in improving cardiovascular outcomes, reducing weight, and targeting treatments for the mediating pathways of hyperglycemia.

In this week’s Homerun Slides, we continue our short series on introducing SGLT-2 inhibitor therapy to your patients. Topics this week include: Practical Clinical Approaches To Maximize Benefits and Minimize Risks… To download the complete set in PowerPoint format, just use this link: Discussion of Practical Implementation of SGLT-2’s with a Patient, …

In this week’s Homerun Slides, we continue our short series on introducing SGLT-2 inhibitor therapy to your patients. Topics this week include: Logic for SGLT-2 Inhibition, But Won’t Sugar Hurt My Kidneys, and CV Risk factor Changes with SGLT-2 Inhibitors…

A short series, courtesy Dr. Stanley Schwartz, on discussing SGLT-2 inhibitor therapy with your patients

In this week’s Homerun Slides, we talk about some of the Potential Adjunctive Treatments for Type 1 Diabetes including: Incretins, SGLT-2 Inhibitors, and Insulin Sensitizers…. 

In this week’s Homerun Slides, we focus exclusively on Pramlintide as a treatment therapy for type 1 diabetes including topics on how Pramlintide Reduces Postprandial Glucagon; Clinical Effects; and the Safety and Tolerability in Type 1 Diabetes….